New patient-centric solution for the management of chronic respiratory insufficiency diseases

November 16, 2012

Philips Respironics today announces the availability of the new bi-level ventilator BiPAP A401 for the management of chronic respiratory insufficiency, a condition secondary to diseases such as obesity hypoventilation syndrome, chronic obstructive pulmonary disease (COPD) and neuromuscular disease for adult and pediatric patients (above 10 kg).

Launching on World COPD Day 2012 and being showcased this week at Medica 2012, the world's largest medical trade fair, the BiPAP A40 improves the management of chronic respiratory diseases by offering a range of unique benefits that facilitate the smoothest possible transition in the patient care pathway – from initial titration to , from home therapy to long-term follow-up.

"Philips is proud to be able to provide access to new and innovative solutions that improve quality of care for respiratory patients – both in hospital and at home," comments Mats Dahlquist, general manager international, Philips Home Healthcare Solutions.

One of the key benefits of the BiPAP A40 is an innovative ventilation mode called AVAPS-AE, which helps to guide clinicians during the initial titration of therapy, while maintaining comfort and improving efficacy for the patient. This new ventilation mode automatically maintains airway patency while delivering the correct level of ventilation each user requires, whatever their body position or sleep stage. AVAPS-AE mode also helps to guide clinicians during the initial titration of therapy, while providing long term comfort and assuring therapy compliance.

In addition to the introduction of AVAPS-AE, the BiPAP A40 features a unique battery module design which provides users with an enhanced level of autonomy that increases support when traveling, or in the case of a power shortage. Furthermore, the design incorporates an intuitive user interface and data management tools that allow clinicians to remotely access and review data about a user's therapy, adjusting it as necessary. This can help to reduce therapy drop out and the associated risk of hospital re-admission.

Although many are preventable and can be effectively managed, they continue to be an important cause of morbidity, mortality and the increased health care costs worldwide. COPD is predicted to become the third leading cause of death worldwide by 2030, with 65 million people currently living with the disease across the world. "COPD is a particularly costly disease to manage, with an annual healthcare bill of more than 10 billion Euros across the EU alone."

Explore further: New evidence highlights risk of comorbidities for COPD patients

More information: Wouters EFM. Economic analysis of the confronting COPD survey: an overview of results. Respir Med 2003; 97:S3-S14.
www.philips.com/BiPAP

Related Stories

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.